Local immunotherapy — Experimental and clinical research

  • Jürgen Bier
  • Stephen J. Kleinschuster
  • Joost Ruitenberg
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 22)

Abstract

Numerous immunostimulants are able to influence the growth of transplanted syngeneic or autochthonous malignant tumors. This also includes living and dead bacterial components.

Keywords

Drain Lymph Node Bacillus Calmette Guerin Mycobacterium Bovis Bacillus Calmette Guerin Vaccination Progressive Tumor Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nauts HC: The apparently beneficial effects of bacterial infection on host resistance to cancer. NY Cancer Res Inst Monogr 1: 1, 1969.Google Scholar
  2. 2.
    Nauts HC: The apparently beneficial effects of bacterial infection on host resistance to cancer. NY Cancer Res Inst Monogr 2: 373, 1969.Google Scholar
  3. 3.
    Coley WB: Further observations upon the treatment of malignant tumors with the toxin of erysipelas and Bacillus prodigiosus, with a report of 160 cases. Bull Johns Hopkins Hosp 65: 157, 1896.Google Scholar
  4. 4.
    Nauts HC, Fowler GA, Bogatka F: A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man. Acta Med Scand 276: 5, 1953.Google Scholar
  5. 5.
    Guérin C: In: Rosenthal SR (ed) The History of BCG. BCG Vaccination Against Tuberculosis. Boston, Little, Brown and Company 1957, p48.Google Scholar
  6. 6.
    Crispen RG: Immunoprophylaxis with BCG. In: Crispen RG (ed) Neoplasm Immunity: BCG vaccination. Chicago, 111., Schori Press, 1974.Google Scholar
  7. 7.
    Eickhoff TC: The current status of BCG immunization against tuberculosis. Annu Rev Med 28: 411, 1977.PubMedGoogle Scholar
  8. 8.
    Dubos RJ, Shaedler RW: Effects of cellular constituents of mycobacteria on resistance of mice to heterologous infections. I. Protective effect. J Exp Med 106: 703, 1957.PubMedGoogle Scholar
  9. 9.
    Brown JAK, Stone MM, Sutherland J: BCG vaccination of children against leprosy in Uganda: results at end of second follow-up. Br Med J 1: 24, 1968.PubMedGoogle Scholar
  10. 10.
    Biozzi G, Benacerraf B, Grumbach F: Étude de l’activité granulopexique du systeme reti- culo-endo thelial au cours de Finfection tuberculeuse experimentale de la souris. Ann Inst Pasteur 87: 291, 1954.Google Scholar
  11. 11.
    Old, LJ, Clarke DA, Benacerraf B: Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature (Lond) 184: 291, 1959.Google Scholar
  12. 12.
    Weiss, DW, Bonhag RS, De Que, KB: Protective activity of fractions of tubercle bacilli against isologous tumours in mice. Nature (Lond) 190: 889, 1961.Google Scholar
  13. 13.
    Suter E: Passive transfer of acquired resistance to infection with mycobacterium tuberculosis by means of cells. Am Rev Respir Dis 83: 535, 1961.Google Scholar
  14. 14.
    Millmann I: Passive transfer of resistance to tuberculosis. Am Rev Respir Dis 85: 30, 1962.Google Scholar
  15. 15.
    Fong J, Chin D, Elberg SS: Studies on tubercle bacillus-histiocyt relationship. V. Passive transfer of cellular resistance. J Exp Med 115: 475, 1962.PubMedGoogle Scholar
  16. 16.
    Lefford MJ, McGregor DD, MacKaness GB: Immune response to Mycobacterium tuberculosis in rats. Infect Immun 8: 182, 1973.PubMedGoogle Scholar
  17. 17.
    Lederer E, Adam A, Ciorbaru R, Petit JF, Wietzerbin J: Cell walls of Mycobacteria and related organisms; chemistry and immunostimulant properties. Moll Cell Biochem 7: 87, 1975.Google Scholar
  18. 18.
    Minden P, McClatchy JK, Cooper R, Bardane EJ, Farr RS: Shared antigens between Mycobacterium bovis (BCG) and other bacterial species. Science 176: 57, 1972.PubMedGoogle Scholar
  19. 19.
    Minden P, Sharpton TR, McClatchy JK: Shared antigens between bacteria and guinea pig line 10 hepatocarcinoma cells. Cancer Res 36: 1680, 1976.PubMedGoogle Scholar
  20. 20.
    Borsos T, Rapp HJ: Antigenic relationship between Myobacterium bovis (BCG) and guinea pig hepatoma. J Natl Cancer Inst 51: 1085, 1973.PubMedGoogle Scholar
  21. 21.
    v. Rokitansky C (ed): A manual of pathological anatomy. Blanchard u. Lea, Philadelphia, 1855.Google Scholar
  22. 22.
    Pearl R: Cancer and tuberculosis. Am J Hyg 9: 97, 1929.Google Scholar
  23. 23.
    Old LJ, Benacerraf B, Clarke DA, et al: The role of the veticuloendothelial system in the host reaction to neoplasia. Cancer Res 21: 1281, 1961.PubMedGoogle Scholar
  24. 24.
    Hattori S, Matsuda M: Relationship between cancer and tuberculosis II. A retarding effect of BCG inoculation for tumor induction in mice with INH or urethane-4NQO injections. Kekkaku 39: 449, 1964.PubMedGoogle Scholar
  25. 25.
    Inooka SJ: Relation between tumor growth and host resistance. Sci Rep Res Inst Tohoku Univ (Med) 12: 240, 1965.Google Scholar
  26. 26.
    Piessens WF, Heimann R, Legros N, et al: Effect of Bacillus Calmette-Guerin on mammary tumor formation and cellular immunity in dimethylbenz-(a)anthracene-treated rats. Cancer Res 31: 1061, 1971.PubMedGoogle Scholar
  27. 27.
    Weiss DW: Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli. Natl Cancer Inst Monogr 35: 157, 1972.PubMedGoogle Scholar
  28. 28.
    Kataoka T, Nakamura RM, Yamamoto S, et al: Effect of BCG on carcinogen-induced tumor development in mice. Jap J Med Sci Biol 25: 377, 1972.PubMedGoogle Scholar
  29. 29.
    Vollegov Al: Local intensification of cellular immunological reaction and resistance to the development of neoplasms. Vestn Akad Med Nauk SSSR 27 (2): 91, 1972.Google Scholar
  30. 30.
    Lavrin DH, Rosenberg SA, Conner RJ: Immunoprophylaxis of methylcholanthrene- induced tumors in mice with Bacillus Calmette-Guerin an methanol-extracted residue. Cancer Res 33: 472, 1973.PubMedGoogle Scholar
  31. 31.
    Lemonde P, Clode M: Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Bid Med 111: 739, 1962.Google Scholar
  32. 32.
    Lemonde P, Clode-Hyde M: Influence of Bacille Calmette-Guerin infection on polyoma in hamsters and mice. Cancer Res 26: 585, 1966.PubMedGoogle Scholar
  33. 33.
    Sjögren HO, Ankerst J: Effect of BCG and allogeneic tumor cells on adenovirus typ 12 tumorigenesis in mice. Nature (Lond) 221: 863, 1969.Google Scholar
  34. 34.
    Lemonde P: Protective effects of BCG and other bacteria against neoplasia in mice and hamsters. Natl Cancer Inst Monogr 39: 21, 1973.PubMedGoogle Scholar
  35. 35.
    Schwartz DB, Zbar B, Gibson WT, et al.: Inhibition of murine sarcom virus oncogenesis with living BCG. Int J Cancer 8: 320, 1971.PubMedGoogle Scholar
  36. 36.
    Larson CL, Ushijima RN, Florey MJ, et al.: Effect of BCG on Friend disease virus in mice. Nature (New Biol) 229: 243, 1971.Google Scholar
  37. 37.
    Larson CL, Baker RE, Ushijima RN, et al.: Immunotherapy of Friend disease in mice employing viable BCG vaccine. Proc Soc Exp Bid Med 140:700, 1972.Google Scholar
  38. 38.
    Ankerst J, Jonsson N: Inhibitory effects of BCG on adenovirus tumorigenesis: dependence on administration schedule. Int J Cancer 10: 351, 1972.PubMedGoogle Scholar
  39. 39.
    Houchens DP, Goldberg Al, Gaston MR, et al.: Studies of the effect of Bacillus Calmette- Guerin on Moloney sarcoma virus-induced tumors in normal and immuno-suppressed mice. Cancer Res 33: 685, 1973.PubMedGoogle Scholar
  40. 40.
    Haran-Ghera N, Weiss BW: Effect of treatment of C57BL76 mice with the methanol extraction residue fraction of BCG on leukemogenesis induced by the radiation leukemia virus. J Natl Cancer Inst 50: 229, 1973.PubMedGoogle Scholar
  41. 41.
    Nilson A, Revesz L, Stjernsward J: Suppression of Strontium-90-induced development of bone tumors by infection with Bacillus Calmette-Buerin (BCG). Radiat Res 26: 378, 1965.Google Scholar
  42. 42.
    Weiss DW, Lavrin DH, Dezfulian M, et al.: Studies on the immunology of spontaneous mammary carcinomas of mise. In: Burdette WJ (ed) Viruses Inducing Cancer. Salt Lake City, University of Utah Press, 1968, p 138.Google Scholar
  43. 43.
    Lavrin DH, Rosenberg SA, Conner RJ: Immunoprophylaxis of methylcholanthrene- induced tumors in mice with Bacillus Calmette-Guerin and methanol-extracted residue. Cancer Res 33: 472, 1973.PubMedGoogle Scholar
  44. 44.
    Helpern Bn, Biozzi G, Stiffel C, et al.: Effet de la stimulation du systeme reticuloendothelial par Tinoculation du bacille Calmette-Guerin sur le developpement de l’epithelioma atypique T-8 de Guerin chez le rat. C R Soc Biol (Paris) 153: 919, 1959.Google Scholar
  45. 45.
    Biozzi G, Stiffel C, Halpern BN, et al: Effet de Tinoculation du bacille de Calmette-Guerin sur le developpement de la tumeur ascilique d’Ehrlich chez la souris. C R Soc Bid (Paris) 153: 987, 1959.Google Scholar
  46. 46.
    Old LJ, Clarke DA, Benacerraf B, et al.: The reticuloendothelial system and the neoplastic process. Ann N Y Acad Sci 88: 264, 1960.Google Scholar
  47. 47.
    Old LJ, Clarke DA, Benacerraf B: Effect of prior splenectomy on the growth of sarcoma 180 in normal and Bacillus Calmette-Guerin infected mice. Experientia 18: 335, 1962.PubMedGoogle Scholar
  48. 48.
    Weiss DW, Bonhag RS, Leslie P: Studies on the heterologous immunogenicity of a metha- nol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts. J Exp Med 124: 1039, 1966.PubMedGoogle Scholar
  49. 49.
    Klein E: Hypersensitivity reactions at tumor site. Cancer Res 29: 2351, 1969.PubMedGoogle Scholar
  50. 50.
    Klein E, Holtermann OA, Papermaster B, Milgrom H, Rosner D, Klein L, et al.: Immunologic approaches to various types of cancer with the use of BCG and purified protein derivates. Natl Cancer Inst Monogr 39: 229, 1973.PubMedGoogle Scholar
  51. 51.
    Klein E, Holtermann OA, Heim F, Rosner D, Milgram H, Adler S, et al.: Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: Review of ten Year program. In: Cancer and Transplantation. NY, Grune and Stratton, 1975.Google Scholar
  52. 52.
    Zbar B, Bernstein I, Tanaka T, et al.: Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science 170: 1217, 1970.PubMedGoogle Scholar
  53. 53.
    Zbar B, Bernstein I, Rapp HJ: Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guerin. J Natl Cancer Inst 46: 831, 1971.PubMedGoogle Scholar
  54. 54.
    Bartlett GL, Zbar B: Tumor-specific vaccine containing mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48: 1709, 1972.PubMedGoogle Scholar
  55. 55.
    Littmann BH, Meltzer MS, Cleveland RP: Tumor-specific, cell-mediated immunity in guinea pigs with tumors. J Natl Cancer Inst 51: 1627, 1973.Google Scholar
  56. 56.
    Tanaka T, Tokunaga T: Suppression of tumor growth an induction of specific tumor immunity by intradermal inoculation of a mixture of living tumor cells and life Mycobacterium bovis in syngenic mice. Gann 62: 433, 1971.PubMedGoogle Scholar
  57. 57.
    Tokunaga T, Kataoka T, Nakamura RM, et al: Tumor immunity induced by BCG-tumor cell mixtures in syngenic mice. Jap J Med Sci Bid 26: 71, 1973.Google Scholar
  58. 58.
    Chung EB, Zbar B, Rapp HJ: Tumor regression mediated by Mycobacterium bovis (strain BCG): effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum. J Natl Cancer Inst 51: 241, 1973.PubMedGoogle Scholar
  59. 59.
    Baldwin RW, Pimm MV: Influence of BCG infection on growth of 3-methyl-cholanthrene- induced rat sarcomas. Rev Eur Etud Clin Biol 16: 875, 1971.PubMedGoogle Scholar
  60. 60.
    Baldwin RW, Pimm MV: BCG immunotherapy of local subcutaneous growth and postsurgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer 12: 420, 1973.PubMedGoogle Scholar
  61. 61.
    Zbar B, Tanaka T: Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172: 271, 1971.PubMedGoogle Scholar
  62. 62.
    Zbar B, Rapp HJ, Ribi E: Tumor suppression by cell walls of Mycobacterium bovis attached to oil droplets. J Natl Cancer Inst 48: 831, 1972.PubMedGoogle Scholar
  63. 63.
    Zbar B: Tumor regression mediated by Mycobacterium bovis (strain BCG). Natl Cancer Inst Monogr 35: 341, 1972.PubMedGoogle Scholar
  64. 64.
    Zbar B, Ribi E, Rapp HJ: An experimental model for immunotherapy of cancer. Natl Cancer Inst Monogr 39: 3, 1973.PubMedGoogle Scholar
  65. 65.
    Hanna MG Jr, Peters LC: Efficacy of intralesional BCG therapy in guinea pigs with disseminated tumor. Cancer 36: 1298, 1975.PubMedGoogle Scholar
  66. 66.
    Morton DL, Eibler FR, Homes EC, et al: BCG immunotherapy of malignant melanoma:Google Scholar
  67. 67.
    Summary of a seven year experience. Annal Surg 180 (4): 635, 1974.Google Scholar
  68. 68.
    Bast RC Jr, Zbar B, Borsos T, Rapp HJ: BCG and cancer. New Engl J Med 290:1413,Google Scholar
  69. 69.
  70. 70.
    Hunter-Craig I, Newton KA, Westbury G, Lacey BW: Use of vaccina virus in the treatment of metastatic.malignant melanoma. Brit Med J 2:512, 1970. Everall JD, Wand J, O’Doherty CJ, Dowd PM: Treatment of primary melanoma by intralesional vaccina before excision. Lancet 2: 583, 1975.Google Scholar
  71. 71.
    Tokunaga T, Kataoka T, Nakamura RM, et al: Tumor immunity induced by BCG-tumor cell mixtures in syngenic mice. Jap J Med Sci Bid 26: 71, 1973.Google Scholar
  72. 72.
    Yamamura Y, Azuma I, Tariyama T, Ribi E, Zbar B: Suppression of tumor growth and regression of established tumor with oil attached Mycobacterial fractions. Gaun 65: 179, 1974.Google Scholar
  73. 73.
    Scott MT: Corynebacterium parvum as an immuno therapeutic anticancer agent. Sem Oncol 1: 367, 1974.Google Scholar
  74. 74.
    Scott MT: Corynebacterium parvum as a therapeutic antitumor agent in mice: I. Systemic effects from intravenous injection. J Natl Cancer Inst 53:855, 1974. Scott MT: Corynebacterium parvum as a therapeutic antitumor agent in mice: II. Local injection. J Natl Cancer Inst 53: 861, 1974.Google Scholar
  75. 75.
    Likhite VV, Halpern BN: Lasting rejection of mammary adeno carcinoma cell tumors in DBA/2 mice with intratumor injection of killed Corynebacterium parvum. Cancer Res 34: 341, 1974.PubMedGoogle Scholar
  76. 76.
    Youdim S, Moser M, Stutman O: Non-specific suppression of tumor growth by an immune reaction to Listeria monocytogenes. J Natl Cancer Inst 52: 193, 1974.PubMedGoogle Scholar
  77. 77.
    Bast RC Jr, Zbar B, MacKanness GB, Rapp HJ: Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst 54: 749, 1975.Google Scholar
  78. 78.
    Bast RC Jr, Zbar B, Miller TE, MacKaness GB, Rapp HJ: Antitumor activity of bacterial infection. II. Effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst 54: 757, 1975.PubMedGoogle Scholar
  79. 79.
    Likhite VV: Rejection of mammary adenocarcinoma cell tumors and prevention of progressive growth of incipient metastases following intratumor permeation with killed Bor- datella pertussis. Cancer Res 34: 2790, 1974.PubMedGoogle Scholar
  80. 80.
    Hanna MG, Snodgrass MJ, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of mycobacterium bo vis. IV. Development of immunity to tumor cells and BCG. J Natl Cancer Inst 51: 1897, 1973.PubMedGoogle Scholar
  81. 81.
    Sparks FC, O’Connell TX, Lee YT: Adjuvant preoperative and postoperative immunoche- motherapy for mammary adenocarcinoma in rats. Surg Forum 24: 118, 1973.PubMedGoogle Scholar
  82. 82.
    Baldwin RW, Pimm MV: BCG immunotherapy of rat tumors of defined immunogenicity. Natl Cancer Inst Monogr 39: 11, 1973.PubMedGoogle Scholar
  83. 83.
    Baldwin RW, Pimm MV: BCG immunotherapy of pulmonary growth from intravenously transferred rat tumor cells. Brit J Cancer 27: 48, 1973.PubMedGoogle Scholar
  84. 84.
    Baldwin RW, Pimm MV: BCG immunotherapy of local subcutaneous growth and postsurgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer 12: 420, 1973.PubMedGoogle Scholar
  85. 85.
    Zbar B, Ribi E, Kelly M, Granger D, Evans C, Rapp HJ: Immunologic approaches to the treatment of human cancer based on a guinea pig model. Cancer immunol Immunother 1: 127, 1976.Google Scholar
  86. 86.
    Smith HJ, Bast RC Jr, Zbar B, Rapp HJ: Eradication of microscopic lymph node metastases after injection of living BCG adjacent to the primary tumor. J Natl Cancer Inst 55: 1345, 1975.PubMedGoogle Scholar
  87. 87.
    Littman B, Zbar B, Rapp HJ: Effects of Mycobacterium bovis (BCG) on tumor cell growth in muscle. Proc Am Ass Cancer Res 13: 96, 1972.Google Scholar
  88. 88.
    Harmel RP Jr, Zbar B, Rapp HJ: Suppression and regression of a transplanted tumor in the guinea pig colon mediated by Mycobacterium bovis, strain BCG. J Natl Cancer Inst 54: 515, 1975.PubMedGoogle Scholar
  89. 89.
    Kleinschuster SJ, Rapp HJ, Lueker DC, Kainer R: Regression of bovine ocular carcinoma by treatment with a mycobacterial vaccine. J Natl Cancer Inst 58: 1807, 1977.PubMedGoogle Scholar
  90. 90.
    Simmons RL, Rios A, Kersey JH: Regression of spontaneous mammary carcinomas using direct injections of neuramidase and BCG. J Surg Res 12: 57, 1972.PubMedGoogle Scholar
  91. 91.
    Bier J, Bitter K, Nicklisch U: Immundefekte bei Patienten mit Plattenepithelkarzinomen der Mundhohle. Dtsch Z Mund-Kiefer-Gesichts-Chir 1: 210, 1977.Google Scholar
  92. 92.
    Fries R, Platz H, Wagner R, Stickler A, et al: Karzinome der Mundhohle. Zur Frage der Abhangigkeit der Prognose von der Lokalisation (Etagen und Bezirke) des Primartumors. Dtsch Z Mund-Kiefer-Gesichts-Chir 1: 127, 1977.Google Scholar
  93. 93.
    Aungst CW, Sokal JE, Jager BV: Complications of BCG vaccination. Proc Am Assoc Cancer Res 14: 108, 1973.Google Scholar
  94. 94.
    Russel WO, Wynne ES, Loguvam GS: Studies on bovine ocular squamous carcinoma (‘cancer eye’). I. Pathological anatomy and historical review. Cancer 9: 1, 1956.Google Scholar
  95. 95.
    Lush JL: Red-eyed Herefords preferred; sunlight shown to be hard on white-eyed and white-skinned animals in southern latitudes. Breed Gaz 88: 489, 1925.Google Scholar
  96. 96.
    Guilbert HR, Wahid A, Wagnon KA, Gregory PW: Observations on pigmentation of eyelids of Hereford cattle in relation to occurrence of ocular epitheliomas. J Animal Sc 7: 426, 1948.PubMedGoogle Scholar
  97. 97.
    Craig J: Disease of dairy cattle: Warts and eye cancer. J Deps Agri West Australia 1: 861, 1952.Google Scholar
  98. 98.
    Kinsley AT: Ocular tumors with case reports. Am Vet Rev 43: 291, 1913.Google Scholar
  99. 99.
    Nair KP, Sastry GA: A survey of animal neoplasms in the Madras State. I. Bo vines, Indian Vet J 30: 325, 1954.Google Scholar
  100. 100.
    Hunter (personal communication).Google Scholar
  101. 101.
    Simova J, Bubenik J: Failure of Bacillus Calmette-Guerin (BCG) infection to suppress the growth of transplanted mouse and rat sarcomas. Folia Bid (Prague) 19: 296, 1973.Google Scholar
  102. 102.
    Sparks FC, Breeding JH: Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guerin and neuramidase. Cancer Res 34: 3262, 1974.PubMedGoogle Scholar
  103. 103.
    Zbar (personal communications).Google Scholar
  104. 104.
    Bartlett GL, Zbar B, Rapp HJ: Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guerin strain of Mycobacterium bovis. J Natl Cancer Inst 48: 245, 1972.PubMedGoogle Scholar
  105. 105.
    Moore M, Lawrence N, Witherow PJ: Suppression of transplanted rat sarcomata mediated by Bacillus Calmette Guerin (BCG). Eur J Cancer 10: 673, 1974.PubMedGoogle Scholar
  106. 106.
    Ray PK, Poduval TB, Sundaram K: Antitumor immunity. V. BCG-induced growth inhibition of murine tumors. Effect of hydrocortisone, antiserum against theta antigen, and gamma-irradiated BCG. J Natl Cancer Inst 58: 763, 1977.PubMedGoogle Scholar
  107. 107.
    Tanaka T, Nakawaga H, Kato A, et al.: Effect of anti-thymocyte serum, anti-macrophage serum, and latex particles on the therapeutic efficacy of BCG or Corynebacterium liquefa- ciens in syngeneic mice. Gann 68: 45, 1977.PubMedGoogle Scholar
  108. 108.
    Chassoux D, Salomon JC: Therapeutic effect of intratumoral injection of BCG and other substances in rats and mice. Int J Cancer 16: 515, 1975.PubMedGoogle Scholar
  109. 109.
    Moore M, Lawrence N, Nisbet NW: Tumor inhibition mediated by BCG in immunsup- pressed rats. Int J Cancer 15: 897, 1975.PubMedGoogle Scholar
  110. 110.
    Moore M, Lawrence N, Nisbet NW: Inhibition of transplanted sarcomas mediated by BCG in rats with a defined immunological deficit. Biomedicine 24: 26, 1976.PubMedGoogle Scholar
  111. 111.
    MacKaness GB: The influence of immunologically committed lymphocytes on macrophage activity in vivo. J Exp Med 129: 973, 1969.PubMedGoogle Scholar
  112. 112.
    Blanden RV, Lefford MJ, MacKaness: The host response to Calmette-Guerin bacillus in mice. J Exp Med 129: 1079, 1969.PubMedGoogle Scholar
  113. 113.
    Snyderman R, Altmann LC, Hausmann MS, Mergenhagen SE: Human mononuclear leucocyte chemotaxis: A quantitative assay for mediators of humoral and cellular chemotaxis factors. J Immunol 108: 857, 1972.PubMedGoogle Scholar
  114. 114.
    David JR: Lymphocyte mediators and cellular hypersensitivity. N Engl J Med 288: 143, 1973.PubMedGoogle Scholar
  115. 115.
    David JR, Lawrence HS, Thomas L: Delayed hypersensitivity in vitro: II. Effect of sensitive cells on normal cells in the presence of antigen. J Immunol 93: 274, 1964.PubMedGoogle Scholar
  116. 116.
    David JR: Delayed hypersensitivity in vitro: Its mediation by cell-free substance formed by lymphoid cell-antigen interaction. Proc Nat Acad Sci Wash 56: 72, 1966.Google Scholar
  117. 117.
    David JR, Piessens WF, Churchill WH Jr: Macrophage activation by lymphocyte mediators and tumor immunity: a brief review. In: Fink MA (ed) The Macrophage in Neoplasia. New York, Academic Press, 1976, p67.Google Scholar
  118. 118.
    Holtermann OA, Casale GP, Klein E: Tumor cell destruction by macrophages. J Med 3: 305, 1972.PubMedGoogle Scholar
  119. 119.
    Hibbs JB Jr: Macrophage nonimmunologic recognition: Target cell factors related to contact inhibition, cience 180: 868, 1973.Google Scholar
  120. 120.
    Alexander P: Activated macrophages and the antitumor action of BCG. Natl Cancer Inst Monogr 39: 127, 1973.PubMedGoogle Scholar
  121. 121.
    Keller R: Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages. J Exp Med 138: 625, 1973.PubMedGoogle Scholar
  122. 122.
    Heise ER, Weiser RS: Factors in delayed hypersensitivity: Lymphocyte and macrophage cytotoxins in the tuberculin reaction. J Immunol 103: 570, 1969.PubMedGoogle Scholar
  123. 123.
    Pinous WB: Tissue injury and delayed hypersensibility. Ann Allergy 28: 93, 1970.Google Scholar
  124. 124.
    Kramer JJ, Granger GA: The in vitro induction and release of a cell toxin by immune C57BL/6 mouse peretoneal macrophages. Cell Immunol 3: 88, 1972.PubMedGoogle Scholar
  125. 125.
    Ferluga J: Increased cytolytic activity of a subcellular fraction from mouse liver after BCG infection. Lancet 2: 1476, 1973.PubMedGoogle Scholar
  126. 126.
    Gery I, Waksman BH: Potentation of the T-lymphozyte response to mitogens. II. The cellular source of potentating mediator(s). J Exp Med 136: 143, 1972.PubMedGoogle Scholar
  127. 127.
    Mitchell M, Kirkpatrick D, Mohys M, Gery I: On mode of action of BCG. Nature (New Biol) 243: 216, 1973.Google Scholar
  128. 128.
    Calderon JJ, Kiely M, Lefko JL, Unanue ER: The modulation of lymphocyte function by molecules secreted by macrophages. I. Description and partial biochemical analysis. J Exp Med 142: 151, 1975.PubMedGoogle Scholar
  129. 129.
    Bekierkonst A: Immunotherapy and vaccination against cancer with non-living BCG and cord factor (trehalose-6,6’-dimycdate). Int J Cancer 16: 442, 1975.Google Scholar
  130. 130.
    Yarkoni E, Rapp HJ, Zbar B: Immunotherapy of a guinea pig hepatoma with ultrasonically prepared mycobacterial vaccines. Cancer Immunol Immunother 2: 143, 1977.Google Scholar
  131. 131.
    Tanaka T, Saito T: Immunotherapy of cancer: induction of tumor immunity with a mixture of tumor cell-BCG,and the effect of intratumor injection of BCG and of nonliving BCG-preparations. Gann 66: 631, 1975.PubMedGoogle Scholar
  132. 132.
    Embleton MJ: Influence of cell-free tumor-associated antigen preparations on the devel- opement of immunity to chemically induced rat tumors. Int J Cancer 18: 622, 1976.PubMedGoogle Scholar
  133. 133.
    Hawrylko E: Influence of BCG potentatiated immunotherapy in tumor bearing mice. J Natl Cancer Inst 59: 359, 1977.Google Scholar
  134. 134.
    Pellis NR, Kahan BD: Specific tumor immunity induced with soluble materials: restricted range of antigen dose and of challenge tumor load for immunoprotection. J Immunol 115: 1717, 1976.Google Scholar
  135. 135.
    Price MR, Baldwin RW: Tumor-specific, complement dependant serum cytotoxicity against a chemically induced rat sarcoma. Int J Cancer 20: 284, 1977.PubMedGoogle Scholar
  136. 136.
    Rao VS, Bonavida B: Detection of soluble tumor-associated antigens in serum of tumor- bearing rats and their immunological role in vivo. Cancer Res 37: 3385, 1977.Google Scholar
  137. 137.
    Price MR, Preston VE, Robins RA, Zollner M, Baldwin RW: Induction or immunity to chemically-induced rat tumors by cellular or soluble antigens. Cancer Immunol Immunother 3: 247, 1978.Google Scholar
  138. 138.
    Pimm MV, Baldwin RW: Influence of whole body irradiation on BCG contact suppression of a rat sarcoma and tumor-specific immunity. Br J Cancer 34: 453, 1976.PubMedGoogle Scholar
  139. 139.
    Hopper DG, Pimm MV, Baldwin RW: Silica abrogation of mycobacterial adjuvant contact suppression of tumor growth in rats and athymic mice. Cancer Immunol Immunoth 1: 143, 1976.Google Scholar
  140. 140.
    Bomford R: Active specific immunotherapy of mouse methylcholanthrene induced tumors. Br J Cancer 32: 551, 1975.PubMedGoogle Scholar
  141. 141.
    Rella W, Chaput B: Immunotherapy with tumor cells and BCG in the guinea pig, studied by immunological in vitro and in vivo experiments. Oncology 35: 136, 1978.PubMedGoogle Scholar
  142. 142.
    Spredbrow PB, Wilson BE, Hoffmann D, Kelly WR, Francis J: Immunotherapy of bovine ocular squamous cell carcinomas. Vet Record 100: 376, 1977.Google Scholar
  143. 143.
    Maurer L, Mclntyre O, Rueckert F: Spontaneous regression of malignant Melanoma. Pathologic and Immunologic study in a ten year survivor. Am J Surg 127: 286, 1974.Google Scholar
  144. 144.
    Bulkley GB, Cohen MH, Banks PM, et al: Long-term spontaneous regression of malignant melanoma with visceral metastases. Cancer 36: 485, 1975.PubMedGoogle Scholar
  145. 145.
    Bodurtha AJ, Berkelhammer J, Kim YH, Laucius JF, Mastrangelo MJ: A clinical, histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer 37: 735, 1976.PubMedGoogle Scholar
  146. 146.
    Rosenberg SA, Rapp HJ: Intralesional immnotherapy of melanoma with BCG. Med Clin N Amer 60: 419, 1976.PubMedGoogle Scholar
  147. 147.
    Morton DL, Gilber FR, Malmgren RA, Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68: 159, 1970.Google Scholar
  148. 148.
    Bornstein RS, Mastrangelo MJ, Soilit H, et al: Immunotherapy of melanoma with intralesional BOG. Natl Cancer Inst Monogr 39: 213, 1973.PubMedGoogle Scholar
  149. 149.
    Cohen MH, Jessup JM, Felix El, et al.: Intralesional treatment of recurrent metastatic cutaneous malignant melanoma. Cancer 41: 2456, 1978.PubMedGoogle Scholar
  150. 150.
    Grant RM, Cochran AJ, MacKie R, et al.: Results of administering BCG to patients with melanoma. Lancet 2: 1096, 1974.PubMedGoogle Scholar
  151. 151.
    Krementz ET, Samuels MS, Wallace JH, et al.: Clinical experiences in immunotherapy of cancer. Surg Gynecol Obstet 133: 209, 1971.PubMedGoogle Scholar
  152. 152.
    Levy NL, Mahaley MS, Day ED: Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patients: Assocation with BCG immunotherapy and clinical deterioration. Int J Cancer 10: 244, 1972.PubMedGoogle Scholar
  153. 153.
    Lieberman R, Wybran J, Epstein W: The immunologic and histopathologic changes of BCG-mediated tumor regression in patients, with malignant melanoma. Cancer 35: 756, 1975.PubMedGoogle Scholar
  154. 154.
    Mastrangelo M, Bornstein RS, Sulit H, et al.: Immunotherapy of malignant melanoma. Ann Intern Med 76: 877, 1972.Google Scholar
  155. 155.
    Mastrangelo MJ, Kim YH, NBornstein RS, et al.: Clinical and histologic correlation of melanoma regression after intralesional bCG therapy. J Natl Cancer Inst 52: 19, 1974.PubMedGoogle Scholar
  156. 156.
    Nathanson L: Regression of intradermal malignant melanoma following intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 56: 659, 1972.PubMedGoogle Scholar
  157. 157.
    Pinsky MC, Hirshaut Y, Oettgen HF: Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr 39: 225, 1973.PubMedGoogle Scholar
  158. 158.
    Rosenberg E, Powell R: Active tumor immunotherapy with BCG. South Med J 66: 1359, 1973.PubMedGoogle Scholar
  159. 159.
    Seigler HF, Shingleton WW, Metzgar RS, et al.: Immunotherapy in patients with melanoma. Ann Surg 178: 352, 1973.Google Scholar
  160. 160.
    Smith GV, Morse PA Jr, Derlaps DG: Immunotherapy of patient with cancer. Surgery 74: 59, 1973.PubMedGoogle Scholar
  161. 161.
    Mastiauggelo MJ, Berd D, Bellet RE: Critical review of previously reported clinical trials of cancer immunotherapy with nonspecific immunostimulants. Ann NY Acad Sci 277: 94, 1976.Google Scholar
  162. 162.
    Yamamma Y, Azuma I, Taniyama T, et al.: Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovts-Bacillus-Calmette-Guerin. Ann NY Acad Sci 277: 209, 1976.Google Scholar
  163. 163.
    H63. Richman SP, Gutterman JU, Henk EM, Ribi EE: Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3. Cancer Immunol Immunother 5: 41, 1978.Google Scholar
  164. 164.
    Vosika G, Schmidtke J, Goldman A, et al.: Phase I-II study of intralesional immunotherapy with oil-attached mycobacterium smegmatis call wall skeleton and trehalose dimyco- late. Cancer Immunol Immunother 6: 135, 1979.Google Scholar
  165. 165.
    Mastrangelo M, Bellet RE, Berkelhammer J, et al: Regressions of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36: 1305, 1975.PubMedGoogle Scholar
  166. 166.
    Hunt JS, Silverstein MJ, Sparks F, et al: Granulomatous hepatitis: A complication of BCG immunotherapy. Lancet 2: 820, 1973.PubMedGoogle Scholar
  167. 167.
    McKneally MF, Maver C, Kausel HW: Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1: 377, 1976.PubMedGoogle Scholar
  168. 168.
    Morton DL: Immunological studies with human neoplasms. J Reticuloendothel Soc 10: 137, 1971.PubMedGoogle Scholar
  169. 169.
    Rosenberg Sa, Seipp C, Sears HF: Clinical and immunologic studies of disseminated BCG infection. Cancer 41: 1771, 1978.Google Scholar
  170. 170.
    Morton DL, Holmes EC, Eibler FR, et al: Immunological aspects of neoplasia: A rational basis for immunotherapy. Ann Int Med 74: 587, 1971.Google Scholar
  171. 171.
    Sparks FC: Hazards and complications of BCG immunotherapy. Med Clin N Am 60: 499, 1976.PubMedGoogle Scholar
  172. 172.
    Krown Se, Hilal EY, Pinsky CM, et al: Intralesional injection of the methanol extraction residue or Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer 42: 2648, 1978.PubMedGoogle Scholar
  173. 173.
    Richman SP, Mavligit GM, Wolk R: Epilesional scarification. JAMA 234: 1233, 1975.PubMedGoogle Scholar
  174. 174.
    McKhann CF, Hendrickson CG, Spilter LE, et al: Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection. Cancer 35: 514, 1975.PubMedGoogle Scholar
  175. 175.
    Clifford (personal communication).Google Scholar
  176. 176.
    Sparks FC, Highton A, Hunt JS: Generalized reaction associated with the intratumor injection of BCG. Chest 68: 725, 1975.Google Scholar
  177. 177.
    Robinson JC: Risks of BCG intralesional therapy: An experience with melanoma. J Surg Oncol 9: 587, 1977.PubMedGoogle Scholar
  178. 178.
    Norton JA, Shulman NR, Corash L, et al: Severe thrombozytopenia following intralesional BCG therapy. Cancer 41: 820, 1978.PubMedGoogle Scholar
  179. 179.
    Augnst CW, Sokal JE, Jager BV: Complications of BCG vaccination in neoplastic disease. Ann Intern Med 82: 666, 1975.Google Scholar
  180. 180.
    Hanna MG Jr, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of Mycobacterium bovis: I. Tumor growth and metastasis. J Natl Cancer Inst 48: 1441, 1972.PubMedGoogle Scholar
  181. 181.
    Mansell PWA, Krementz ET: Reactions to BCG. JAMA 226: 1570, 1973.PubMedGoogle Scholar
  182. 182.
    Bodurtha A, Kim YH, Laucius JF, et al: Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. Am J Clin Path 61: 747, 1974.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Jürgen Bier
  • Stephen J. Kleinschuster
  • Joost Ruitenberg

There are no affiliations available

Personalised recommendations